FDA Broke Its Own Rules — Court Refuses Action

Louisiana is appealing a federal judge’s decision that keeps Biden-era mail-order abortion pill rules in place, despite the court acknowledging the state will likely prove the FDA violated proper procedures when it eliminated safety protections.

Story Snapshot

Federal judge paused Louisiana’s lawsuit challenging FDA abortion pill deregulation while Trump’s FDA conducts safety review
Court found Louisiana likely has merit but declined immediate injunction blocking mail-order mifepristone access
Louisiana Attorney General plans appeal to Fifth Circuit to seek restrictions denied at district level
FDA must report on safety review progress by October 2026, creating six-month window of regulatory uncertainty

Court Acknowledges FDA Violations While Denying Immediate Relief

U.S. District Judge David Joseph, a Trump appointee, issued a ruling on April 7, 2026, that acknowledged Louisiana’s concerns about FDA procedural violations while simultaneously refusing to block mail-order abortion pill access. The court found Louisiana has standing and is likely to succeed on claims that the FDA improperly removed in-person medical oversight requirements and expanded mail-order distribution without adequate safety data. Despite recognizing these serious concerns, Judge Joseph granted the Trump administration’s request to pause the litigation while the FDA conducts its own safety review of mifepristone.

Biden-Era Deregulation Eliminated Safety Protections

The 2023 FDA rule changes under the Biden administration removed key safeguards that had governed mifepristone distribution for over two decades. These changes eliminated requirements for in-person medical consultations before prescribing the abortion pill and allowed nationwide mail-order distribution without physician oversight. Louisiana’s lawsuit argues these modifications created dangerous conditions where women could be coerced into taking abortion pills obtained through the mail, citing specific Louisiana residents like Rosalie Markezich who claimed such coercion occurred. The state also contends it suffers financial harm through Medicaid costs associated with abortion pill complications.

Louisiana Plans Fifth Circuit Appeal

Attorney General Liz Murrill announced immediate plans to appeal the district court’s decision to the U.S. Court of Appeals for the Fifth Circuit, seeking the injunction Judge Joseph denied. The Fifth Circuit has previously recognized flaws in FDA abortion pill regulations, potentially making it more receptive to Louisiana’s arguments. Louisiana is one of thirteen states with complete abortion bans at all stages of pregnancy, creating direct conflict with federal rules allowing mail-order abortion pill access. The state’s legal strategy emphasizes protecting both women’s health and state sovereignty against federal regulatory overreach that undermines Louisiana’s democratically enacted laws.

Regulatory Uncertainty Extends Through October

The temporary stay creates a six-month period during which the Trump administration’s FDA must conduct a safety review and report findings to the court by October 7, 2026. Judge Joseph indicated the balance of legal factors “could shift if FDA review lags,” suggesting the pause depends on meaningful progress. Two other similar legal challenges to mifepristone access are pending alongside Louisiana’s case, reflecting broader state-level resistance to Biden-era deregulation. Any restrictions resulting from the FDA review could affect abortion and miscarriage care access nationwide, even in states where abortion remains legal, demonstrating how federal regulatory decisions override state autonomy regardless of local voters’ preferences.

The case exposes fundamental tensions between federal bureaucratic power and state authority, with unelected FDA officials under the previous administration having eliminated safety requirements over objections from states where voters enacted abortion restrictions. While abortion rights advocates claim mifepristone has been safely used for twenty-five years, Louisiana argues the Biden FDA’s 2023 changes went beyond established safety protocols by removing physician oversight entirely. The outcome of the Trump administration’s review will determine whether federal regulators restore common-sense medical safeguards or continue policies that prioritize ideological goals over women’s health and state sovereignty.